Who are Intravenous iclaprim's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sulfamethoxazole / Trimethoprim Injectable Product, Sulfamethoxazole Trimethoprim Combination, Sulfamethoxazole-Trimethoprim, SMZ/TMP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-iclaprim.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intravenous iclaprim — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous iclaprim (Intravenous iclaprim) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dihydrofolate reductase inhibitor. Area: Infectious Disease.

phase 3 Dihydrofolate reductase inhibitor Dihydrofolate reductase (DHFR) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous iclaprim (Intravenous iclaprim) — Arpida AG. Iclaprim is a dihydrofolate reductase (DHFR) inhibitor that disrupts bacterial folate metabolism, preventing DNA synthesis and bacterial growth.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous iclaprim TARGET	Intravenous iclaprim	Arpida AG	phase 3	Dihydrofolate reductase inhibitor	Dihydrofolate reductase (DHFR)
Sulfamethoxazole / Trimethoprim Injectable Product	Sulfamethoxazole / Trimethoprim Injectable Product	Fundacion Clinic per a la Recerca Biomédica	marketed	Sulfonamide + dihydrofolate reductase inhibitor combination	Dihydropteroate synthase and dihydrofolate reductase
Sulfamethoxazole Trimethoprim Combination	Sulfamethoxazole Trimethoprim Combination	Baylor Research Institute	marketed	Sulfonamide-dihydrofolate reductase inhibitor combination	Dihydropteroate synthase; Dihydrofolate reductase
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole-Trimethoprim	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Sulfonamide-dihydrofolate reductase inhibitor combination	Dihydropteroate synthase; Dihydrofolate reductase
SMZ/TMP	SMZ/TMP	First Affiliated Hospital of Zhejiang University	phase 3	Sulfonamide and dihydrofolate reductase inhibitor combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dihydrofolate reductase inhibitor class)

Arpida AG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous iclaprim — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-iclaprim. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab